{"title_page": "Autoimmune lymphoproliferative syndrome", "text_new": "{{Infobox medical condition (new)\n| name            = Autoimmune lymphoproliferative syndrome\n| synonyms        = '''Canale-Smith syndrome''',<ref name=\"Straus2001\">{{cite journal | author = Straus SE, Jaffe ES, Puck JM | display-authors = etal | date = Jul 2001 | title = The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis | url = | journal = Blood | volume = 98 | issue = 1| pages = 194\u2013200 | pmid = 11418480 }}</ref> \n| image           = \n| caption         = \n| pronounce       = \n| field           = \n| symptoms        = \n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = \n| diagnosis       = \n| differential    = \n| prevention      = \n| treatment       = \n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n'''Autoimmune lymphoproliferative syndrome''' ('''ALPS'''), is a form of [[lymphoproliferative disorder]] (LPDs). It affects [[lymphocyte]] [[apoptosis]].<ref name=\"pmid18193364\" />\n\nIt is a rare genetic disorder of abnormal [[lymphocyte]] survival caused by defective [[Fas receptor|Fas]] mediated [[apoptosis]].<ref name=\"pmid16522544\" /> Normally, after infectious insult, the immune system down-regulates by increasing Fas expression on activated B and T lymphocytes and Fas-ligand on activated T lymphocytes. Fas and Fas-ligand interact to trigger the caspase cascade, leading to cell apoptosis. Patients with ALPS have a defect in this apoptotic pathway, leading to chronic non-malignant lymphoproliferation, autoimmune disease, and secondary cancers.<ref name=\"pmid19930184\" />\n\n==Presentation==\nAll people with ALPS have signs of lymphoproliferation, which makes it the most common clinical manifestation of the disease. The increased proliferation of lymphoid cells can cause the size of lymphoid organs such as the [[lymph node]]s and [[spleen]] to increase ([[lymphadenopathy]] and [[splenomegaly]], present in respectively over 90% and over 80% of patients). The [[liver]] is enlarged ([[hepatomegaly]] in 30 - 40% of patients).\n\nAutoimmune disease is the second most common clinical manifestation and one that most often requires treatment. Autoimmune cytopenias: Most common. Can be mild to very severe. Can be intermittent or chronic.<ref name=\"pmid15542578\" /> These include: Autoimmune [[hemolytic anemia]], Autoimmune [[neutropenia]], Autoimmune [[thrombocytopenia]].\n\nOther signs can affect organ systems similar to [[systemic lupus erythematosus]] (least common, affecting <5% of patients) Symptoms of the nervous system include: Autoimmune cerebellar [[ataxia]]; [[Guillain\u2013Barr\u00e9 syndrome]]; [[transverse myelitis]]. Gastrointestinal signs like autoimmune esophagitis, gastritis, colitis, hepatitis, [[pancreatitis]] can be found or (Dermatologic) [[Urticaria]], (Pulmonary) [[bronchiolitis obliterans]], (Renal) [[autoimmune glomerulonephritis]], [[nephrotic syndrome]].\n\nAnother sign are cancers such as [[Hodgkin's lymphoma|Hodgkin]] and [[Non-Hodgkin lymphoma|non-Hodgkin]] lymphomas which appear to be increased,<ref name=\"Straus2001\" /> possibly due to [[Epstein\u2013Barr virus]]-encoded RNA-positivity. Some carcinomas may occur. Unaffected family members with genetic mutations are also at an increased risk of developing cancer.\n\n==Genetics==\nThis condition is usually caused by mutations in the FAS gene. Rarely cases due to mutations in other genes including the \nFAS ligand gene have been reported.<ref name=Magerus-Chatinet2012>Magerus-Chatinet A, Stolzenberg MC, Lanzarotti N, Neven B, Daussy C, Picard C, Neveux N, Desai M, Rao M, Ghosh K, Madkaikar M, Fischer A, Rieux-Laucat F (2012) Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. J Allergy Clin Immunol</ref>\n\n==Diagnosis==\n{{columns-list|colwidth=30em|\n* Elevated peripheral blood Double Negative T cells (DNTs)<ref name=\"pmid12139944\" />\n** Required for diagnosis\n** Immunophenotype: CD3+/CD4-/CD8-/TCRalpha/beta+\n** Measured by [[flow cytometry]]: Normal values <2.5% total T cells; <1% of total lymphocytes in peripheral blood\n** Marked elevations >5% virtually pathognomonic for ALPS\n** Mild elevations also found in other autoimmune diseases\n** Thought to be cytotoxic T lymphocytes that have lost CD8 expression\n** Unknown if driver of disease or epiphenomenon\n** May be falsely elevated in setting of lymphopenia or falsely decreased with immunosuppressive treatment\n* Biomarkers<ref name=\"pmid19176318\" /><ref name=\"pmid20227752\" />\n** Polyclonal [[hypergammaglobulinemia]]<ref name=\"pmid20068224\" />\n** Elevated serum FASL\n** Elevated plasma [[Interleukin 10|IL-10]] and/or IL-18\n** Elevated plasma or serum [[vitamin B12]]\n* [[Autoantibodies]]: Non-specific. Can have antibodies to blood cells (DAT, anti-neutrophil, anti-platelet). Also, can have positive ANA, RF, ANCA\n* Defective in vitro Fas mediated apoptosis\n** Required for diagnosis under old definition. Now can be used to make diagnosis; however, not required to make diagnosis.\n** Time and labor-intensive assay.\n** T cells from patient and normal control supported in culture for >10 days with mitogen stimulation and IL-2 expansion and then exposed to anti-Fas IgM monoclonal antibody\n** ALPS patient T cells: Do not die with anti-Fas monoclonal antibody exposure. Normal T cells from unaffected patient do.\n** False negative in somatic Fas variant ALPS and FasL variant ALPS\n* Genetic mutations in ALPS causative genes (see below)\n}}\n\n===Diagnostic algorithm===\nThe old diagnostic criteria for the illness included:<ref name=\"pmid12819469\" /> Chronic non-malignant lymphoproliferation, elevated peripheral blood DNTs and defective in vitro Fas mediated apoptosis.\n\nThe new criteria<ref name=\"pmid20538792\" /> require chronic non-malignant lymphoproliferation (over six months lymphadenopathy and/or splenomegaly), elevated peripheral blood DNTs. A primary accessory in diagnosis is defective in vitro Fas mediated apoptosis and somatic or germline mutation in ALPS causative gene (FAS, FASL, CASP10).\n\nThe secondary accessory in diagnosis are elevated biomarkers (plasma sFASL over 200 pg/ml, plasma IL-10 >20 pg/ml, plasma or serum vitamin B12 >1500&nbsp;ng/L, Plasma IL-18 >500pg/ml) and immunohistochemical findings on biopsy consistent with ALPS as determined by an experienced hematopathologist. Another sign is autoimmune cytopenias and polyclonal hypergammaglobulinemia and a family history of ALPS or non-malignant lymphoproliferation.\n\nA definitive diagnosis is chronic non-malignant lymphoproliferation and/or elevated peripheral blood DNTs plus one primary accessory criterion. A probable diagnosis is the same but with one secondary accessory criterion.\n\n===Classification===\n2003 nomenclature<ref name=\"pmid12819469\" />\n* IA - [[Fas receptor|Fas]]\n* IB - [[Fas ligand]]\n* IIA - [[Caspase 10]]\n* IIB  - [[Caspase 8]]\n* III - unknown\n* IV - [[Neuroblastoma RAS viral oncogene homolog]]\n\nRevised nomenclature (2010)<ref name=\"pmid20538792\" />\n* ALPS-FAS: Fas. Germline FAS mutations. 70% of patients. Autosomal dominant. Dominant negative and haploinsufficient mutations described.<ref name=\"pmid21490157\" />\n* ALPS-sFAS: Fas. Somatic FAS mutations in DNT compartment.<ref name=\"pmid15459302\" /> 10% of patients\n* ALPS-FASL: [[Fas ligand]]. Germline FASL mutations. 3 reported cases\n* ALPS-CASP10: [[Caspase 10]]. Germline CASP10 mutation. 2% of patients\n* ALPS-U: Undefined. 20% of patients\n* CEDS: Caspase 8 deficiency state. No longer considered a subtype of ALPS but distinct disorder\n* [[RAS-associated autoimmune leukoproliferative disorder|RALD]]: [[Neuroblastoma RAS viral oncogene homolog|NRAS]], [[KRAS]]. Somatic mutations in NRAS and KRAS in lympocyte compartment. No longer considered a subtype of ALPS but distinct disesase\n\n==Treatment==\nTreatment is most commonly directed at autoimmune disease and may be needed to treat bulky lymphoproliferation. First line therapies include [[corticosteroids]] (very active but toxic with chronic use), and IVIgG, which are not as effective as in other immune cytopenia syndromes.\n\nSecond line therapies include: [[mycophenolate mofetil]] (cellcept)<ref name=\"pmid15877736\" /> which inactivates inosine monophosphate, most studied in clinical trials with responses varying (relapse, resolution, partial response). It does not affect lymphoproliferation or reduce DNTs, with no drug-drug interactions. This treatment is commonly used agent in patients who require chronic treatment based on tolerance and efficacy. It may cause hypogammaglobulinemia (transient) requiring IVIgG replacement.\n\n[[Sirolimus]] (rapamycin, rapamune) which is a mTOR ([[mammalian target of rapamycin]]) inhibitor<ref name=\"pmid16757690\" /> can be active in most patients and can in some cases lead to complete or near-complete resolution of autoimmune disease (>90%)<ref name=\"pmid19208097\" /><ref name=\"pmid19588524\" /> With this treatment most patients have complete resolution of lymphoproliferation, including lymphadenopathy and splenomegaly (>90%) and have elimination of peripheral blood DNTs. Sirolimus may not be as immune suppressive in normal lymphocytes as other agents. Some patients have had improvement in immune function with transition from cellcept to rapamycin<ref name=\"pmid21475130\" /> and it has not been reported to cause hypogammaglobulinemia. Hypothetically, Sirolimus may have lower risk of secondary cancers as opposed to other immune suppressants and requires therapeutic drug monitoring. It is the second most commonly used agent in patients that require chronic therapy. It is mostly well tolerated (though side effects include mucositis, diarrhea, hyperlipidemia, delayed wound healing) with drug-drug interactions. It has better activity against autoimmune disease and lymphoproliferation than mycophenolate mofetil and other drugs; however, sirolimus requires therapeutic drug monitoring and can cause mucositis. A risk with any agent in pre-cancerous syndrome as immune suppression can decreased tumor immunosurvellence. Its mTOR inhibitors active against lymphomas, especially EBV+ lymphomas. The Goal serum trough is 5-15&nbsp;ng/ml and can consider PCP prophylaxis but usually not needed.\n\nOther treatments may include drugs like [[Fansidar]],<ref name=\"pmid11918552\" /><ref name=\"pmid17674358\" /> mercaptopurine: More commonly used in Europe. Another is [[rituximab]] but this can cause protracted hypogammaglobulinemia<ref name=\"pmid19214977\" /> and a [[splenectomy]] but there is a >30% risk of pneumococcal sepsis even with vaccination and antibiotic prophylaxis<ref name=\"pmid21885601\" /><ref name=\"pmid21885602\" />\n\n==References==\n{{Reflist|30em|refs=\n<ref name=\"pmid18193364\">{{cite journal |pages=87\u201392 |doi=10.1007/s12026-007-8001-1 |title=The autoimmune lymphoproliferative syndrome: An experiment of nature involving lymphocyte apoptosis |year=2007 |last1=Fleisher |first1=Thomas A. |journal=Immunologic Research |volume=40 |pmid=18193364 |issue=1|url=https://zenodo.org/record/1232880 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid16522544\">{{cite journal |pages=15\u201323 |doi=10.1080/10245330500329094 |title=Causes and consequences of the autoimmune lymphoproliferative syndrome |year=2006 |last1=Rao |first1=V. Koneti |last2=Straus |first2=Stephen E. |journal=Hematology |volume=11 |pmid=16522544 |issue=1|url=https://zenodo.org/record/1234465 }}</ref> \n<ref name=\"pmid19930184\">{{cite journal |pages=205\u201316 |doi=10.1111/j.1365-2141.2009.07991.x |title=Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) |year=2010 |last1=Teachey |first1=David T. |last2=Seif |first2=Alix E. |last3=Grupp |first3=Stephan A. |journal=British Journal of Haematology |volume=148 |issue=2 |pmid=19930184 |pmc=2929682}}</ref> \n<ref name=\"pmid15542578\">{{cite journal |pages=2443\u20138 |doi=10.1182/blood-2004-09-3542 |title=Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS) |year=2005 |last1=Teachey |first1=David T. |journal=Blood |volume=105 |issue=6 |pmid=15542578 |last2=Manno |first2=Catherine S. |last3=Axsom |first3=Kelly M. |last4=Andrews |first4=Timothy |last5=Choi |first5=John K. |last6=Greenbaum |first6=Barbara H. |last7=McMann |first7=Joseph M. |last8=Sullivan |first8=Kathleen E. |last9=Travis |first9=Susan F.|last10=Grupp |first10=S. A. |display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid12139944\">{{cite journal |pages=21\u201330 |doi=10.1006/clim.2002.5225 |title=A Composite Picture of TcR\u03b1/\u03b2<sup>+</sup> CD4<sup>\u2212</sup>CD8<sup>\u2212</sup> T Cells (\u03b1/\u03b2-DNTCs) in Humans with Autoimmune Lymphoproliferative Syndrome |year=2002 |last1=Bleesing |first1=Jack J.H. |last2=Brown |first2=Margaret R. |last3=Novicio |first3=Cynthia |last4=Guarraia |first4=David |last5=Dale |first5=Janet K. |last6=Straus |first6=Stephen E. |last7=Fleisher |first7=Thomas A. |journal=Clinical Immunology |volume=104 |pmid=12139944 |issue=1}}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid19176318\">{{cite journal |pages=3027\u201330 |doi=10.1182/blood-2008-09-179630 |title=FAS-L, IL-10, and double-negative CD4<sup>\u2212</sup>CD8<sup>\u2212</sup> TCR \u03b1/\u03b2<sup>+</sup> T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function |year=2009 |last1=Magerus-Chatinet |first1=Aude |last2=Stolzenberg |first2=Marie-Claude |last3=Loffredo |first3=Maria S. |last4=Neven |first4=B\u00e9n\u00e9dicte |last5=Schaffner |first5=Catherine |last6=Ducrot |first6=Nicolas |last7=Arkwright |first7=Peter D. |last8=Bader-Meunier |first8=Brigitte |last9=Barbot |first9=Jos\u00e9 |last10=Blanche |first10=S. |last11=Casanova |first11=J.-L. |last12=Debre |first12=M. |last13=Ferster |first13=A. |last14=Fieschi |first14=C. |last15=Florkin |first15=B. |last16=Galambrun |first16=C. |last17=Hermine |first17=O. |last18=Lambotte |first18=O. |last19=Solary |first19=E. |last20=Thomas |first20=C. |last21=Le Deist |first21=F. |last22=Picard |first22=C. |last23=Fischer |first23=A. |last24=Rieux-Laucat |first24=F. |journal=Blood |volume=113 |issue=13 |pmid=19176318|display-authors=8 |url=http://bloodjournal.hematologylibrary.org/cgi/reprint/113/13/3027 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid20227752\">{{cite journal |pages=946\u2013949.e6 |doi=10.1016/j.jaci.2009.12.983 |title=Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome |year=2010 |last1=Caminha |first1=Iusta |last2=Fleisher |first2=Thomas A. |last3=Hornung |first3=Ronald L. |last4=Dale |first4=Janet K. |last5=Niemela |first5=Julie E. |last6=Price |first6=Susan |last7=Davis |first7=Joie |last8=Perkins |first8=Katie |last9=Dowdell |first9=Kennichi C. |last10=Brown |first10=Margaret R. |last11=Rao |first11=V. Koneti |last12=Oliveira |first12=Jo\u00e3o Bosco |journal=Journal of Allergy and Clinical Immunology |volume=125 |issue=4 |pmid=20227752|display-authors=8 |pmc=3412519 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid20068224\">{{cite journal |pages=2142\u20135 |doi=10.1182/blood-2009-08-239525 |title=Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: A multi-institutional study |year=2010 |last1=Seif |first1=A. E. |last2=Manno |first2=C. S. |last3=Sheen |first3=C. |last4=Grupp |first4=S. A. |last5=Teachey |first5=D. T. |journal=Blood |volume=115 |issue=11 |pmid=20068224 }}{{MEDRS|date=December 2011}}</ref> \n<ref name=\"pmid12819469\">{{cite journal |pages=417\u201321 |doi=10.1097/00002281-200307000-00008 |title=Autoimmune lymphoproliferative syndrome |year=2003 |last1=Sneller |first1=Michael C. |last2=Dale |first2=Janet K. |last3=Straus |first3=Stephen E. |journal=Current Opinion in Rheumatology |volume=15 |issue=4 |pmid=12819469|url=https://zenodo.org/record/1234778 }}</ref>\n<ref name=\"pmid20538792\">{{cite journal |pages=e35\u201340 |doi=10.1182/blood-2010-04-280347 |pmc=2953894 |title=Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH International Workshop |year=2010 |last1=Oliveira |first1=J. B. |last2=Bleesing |first2=J. J. |last3=Dianzani |first3=U. |last4=Fleisher |first4=T. A. |last5=Jaffe |first5=E. S. |last6=Lenardo |first6=M. J. |last7=Rieux-Laucat |first7=F. |last8=Siegel |first8=R. M. |last9=Su |first9=H. C. |last10=Teachey |first10=D. T. |last11=Rao |first11=V. K. |journal=Blood |volume=116 |issue=14 |pmid=20538792|display-authors=8 }}</ref>\n<ref name=\"pmid21490157\">{{cite journal |pages=6035\u201343 |doi=10.4049/jimmunol.1100021 |title=FAS Haploinsufficiency is a Common Disease Mechanism in the Human Autoimmune Lymphoproliferative Syndrome |year=2011 |last1=Kuehn |first1=H. S. |last2=Caminha |first2=I. |last3=Niemela |first3=J. E. |last4=Rao |first4=V. K. |last5=Davis |first5=J. |last6=Fleisher |first6=T. A. |last7=Oliveira |first7=J. B. |journal=The Journal of Immunology |volume=186 |issue=10 |pmid=21490157|pmc=3725553 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid15459302\">{{cite journal |pages=1409\u201318 |doi=10.1056/NEJMoa040036 |title=Autoimmune Lymphoproliferative Syndrome with SomaticFasMutations |year=2004 |last1=Holzelova |first1=Eliska |last2=Vonarbourg |first2=C\u00e9dric |last3=Stolzenberg |first3=Marie-Claude |last4=Arkwright |first4=Peter D. |last5=Selz |first5=Fran\u00e7oise |last6=Prieur |first6=Anne-Marie |last7=Blanche |first7=St\u00e9phane |last8=Bartunkova |first8=Jirina |last9=Vilmer |first9=Etienne |last10=Fischer |first10=Alain |last11=Le Deist |first11=Fran\u00e7oise |last12=Rieux-Laucat |first12=Fr\u00e9d\u00e9ric |journal=New England Journal of Medicine |volume=351 |issue=14 |pmid=15459302|display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid15877736\">{{cite journal |pages=534\u20138 |doi=10.1111/j.1365-2141.2005.05496.x |title=Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome |year=2005 |last1=Koneti Rao |first1=V. |last2=Dugan |first2=Faith |last3=Dale |first3=Janet K. |last4=Davis |first4=Joie |last5=Tretler |first5=Jean |last6=Hurley |first6=John K. |last7=Fleisher |first7=Thomas |last8=Puck |first8=Jennifer |last9=Straus |first9=Stephen E. |journal=British Journal of Haematology |volume=129 |issue=4 |pmid=15877736 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid16757690\">{{cite journal |pages=1965\u201371 |doi=10.1182/blood-2006-01-010124 |pmc=1895548 |title=Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS) |year=2006 |last1=Teachey |first1=D. T. |journal=Blood |volume=108 |issue=6 |pmid=16757690 |last2=Obzut |first2=DA |last3=Axsom |first3=K |last4=Choi |first4=JK |last5=Goldsmith |first5=KC |last6=Hall |first6=J |last7=Hulitt |first7=J |last8=Manno |first8=CS |last9=Maris |first9=JM|last10=Rhodin |first10=N |last11=Sullivan |first11=K. E. |last12=Brown |first12=V. I. |last13=Grupp |first13=S. A. |display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid19208097\">{{cite journal |pages=101\u20136 |doi=10.1111/j.1365-2141.2009.07595.x |pmc=2819393 |title=Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome |year=2009 |last1=Teachey |first1=David T. |last2=Greiner |first2=Robert |last3=Seif |first3=Alix |last4=Attiyeh |first4=Edward |last5=Bleesing |first5=Jack |last6=Choi |first6=John |last7=Manno |first7=Catherine |last8=Rappaport |first8=Eric |last9=Schwabe |first9=Dirk |last10=Sheen |first10=Cecilia |last11=Sullivan |first11=Kathleen E. |last12=Zhuang |first12=Hongming |last13=Wechsler |first13=Daniel S. |last14=Grupp |first14=Stephan A. |journal=British Journal of Haematology |volume=145 |pmid=19208097 |issue=1|display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid19588524\">{{cite journal |title=Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome |pages=1117\u20139 |year=2009 |last1=Jani\u0107 |first1=MD |last2=Brasanac |first2=CD |last3=Jankovi\u0107 |first3=JS |last4=Dokmanovi\u0107 |first4=BL |last5=Krstovski |first5=RN |last6=Kraguljac Kurtovi\u0107 |first6=JN |volume=53 |issue=6 |doi=10.1002/pbc.22151 |journal=Pediatric Blood & Cancer |pmid=19588524}}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid17674358\">{{cite journal |title=Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome |pages=1049\u201355 |pmid=17674358 |doi=10.1002/ajh.21007 |year=2007 |last1=Rao |first1=V. Koneti |last2=Dowdell |first2=Kennichi C. |last3=Dale |first3=Janet K. |last4=Dugan |first4=Faith |last5=Pesnicak |first5=Lesley |last6=Bi |first6=Lilia L. |last7=Hoffmann |first7=Victoria |last8=Penzak |first8=Scott |last9=Avila |first9=Nilo A. |last10=Fleisher |first10=Thomas A. |last11=Puck |first11=Jennifer M. |last12=Straus |first12=Stephen E. |journal=American Journal of Hematology |volume=82 |issue=12|display-authors=8 }}</ref> \n<ref name=\"pmid11918552\">{{cite journal |pages=176\u201388 |doi=10.1046/j.1365-2141.2002.03357.x |title=Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: Preliminary results of a clinical cohort study and molecular observations |year=2002 |last1=Van Der Werff Ten Bosch |first1=Jutte |last2=Schotte |first2=Peter |last3=Ferster |first3=Alice |last4=Azzi |first4=Nadira |last5=Boehler |first5=Thomas |last6=Laurey |first6=Genevieve |last7=Arola |first7=Mikko |last8=Demanet |first8=Christian |last9=Beyaert |first9=Rudi |last10=Thielemans |first10=Kris |last11=Otten |first11=Jacques |journal=British Journal of Haematology |volume=117 |pmid=11918552 |issue=1|display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid21475130\">{{cite journal|pmid=21475130 |year=2011 |last1=Teachey |first1=David T. |title=Autoimmune Lymphoproliferative Syndrome: New Approaches to Diagnosis and Management |volume=9 |issue=3 |pages=233\u20135 |journal=Clinical Advances in Hematology & Oncology |url=http://www.clinicaladvances.com/index.php/our_publications/hem_onc-article/1956/ |url-status=dead |archiveurl=https://web.archive.org/web/20120426050323/http://www.clinicaladvances.com/index.php/our_publications/hem_onc-article/1956/ |archivedate=2012-04-26 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid19214977\">{{cite journal |pages=847\u201352 |doi=10.1002/pbc.21965 |pmc=2774763 |title=Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS) |year=2009 |last1=Rao |first1=V. Koneti |last2=Price |first2=Susan |last3=Perkins |first3=Katie |last4=Aldridge |first4=Patricia |last5=Tretler |first5=Jean |last6=Davis |first6=Joie |last7=Dale |first7=Janet K. |last8=Gill |first8=Fred |last9=Hartman |first9=Kip R. |last10=Stork |first10=Linda C. |last11=Gnarra |first11=David J. |last12=Krishnamurti |first12=Lakshmanan |last13=Newburger |first13=Peter E. |last14=Puck |first14=Jennifer |last15=Fleisher |first15=Thomas |journal=Pediatric Blood & Cancer |volume=52 |issue=7 |pmid=19214977|display-authors=8 }}</ref>\n<ref name=\"pmid21885601\">{{cite journal |pages=5741\u201351 |doi=10.1182/blood-2011-07-325217 |pmc=3228494 |title=How I treat autoimmune lymphoproliferative syndrome |year=2011 |last1=Rao |first1=V. K. |last2=Oliveira |first2=J. B. |journal=Blood |volume=118 |issue=22 |pmid=21885601}}</ref>\n<ref name=\"pmid21885602\">{{cite journal |pages=4798\u2013807 |doi=10.1182/blood-2011-04-347641 |title=A survey of 90 patients with autoimmune lymphoproliferative syndrome related to ''TNFRSF6'' mutation |year=2011 |last1=Neven |first1=B\u00e9n\u00e9dicte |last2=Magerus-Chatinet |first2=Aude |last3=Florkin |first3=Benoit |last4=Gobert |first4=Delphine |last5=Lambotte |first5=Olivier |last6=De Somer |first6=Lien |last7=Lanzarotti |first7=Nina |last8=Stolzenberg |first8=Marie-Claude |last9=Bader-Meunier |first9=Brigitte |last10=Aladjidi |first10=N. |last11=Chantrain |first11=C. |last12=Bertrand |first12=Y. |last13=Jeziorski |first13=E. |last14=Leverger |first14=G. |last15=Michel |first15=G. |last16=Suarez |first16=F. |last17=Oksenhendler |first17=E. |last18=Hermine |first18=O. |last19=Blanche |first19=S. |last20=Picard |first20=C. |last21=Fischer |first21=A. |last22=Rieux-Laucat |first22=F. |journal=Blood |volume=118 |issue=18 |pmid=21885602|display-authors=8 }}</ref>\n}}\n\n== External links ==\n{{Medical resources\n| DiseasesDB      = 33425\n| ICD10           = \n| ICD9            = {{ICD9|279.41}}\n| ICDO            = \n| OMIM            = 601859\n| OMIM_mult       = {{OMIM2|603909}}\n| MedlinePlus     = \n| eMedicineSubj   = \n| eMedicineTopic  = \n| MeshID          = \n| Orphanet        = 3261\n}}\n\n[[Category:Lymphocytic immune system disorders]]\n[[Category:RASopathies]]\n[[Category:Syndromes with tumors]]\n", "text_old": "{{Infobox medical condition (new)\n| name            = Autoimmune lymphoproliferative syndrome\n| synonyms        = '''Canale-Smith syndrome''',<ref name=\"Straus2001\">Straus SE, Jaffe ES, Puck JM et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001 Jul 1;98(1):194-200. {{PMID|11418480}}</ref> \n| image           = \n| caption         = \n| pronounce       = \n| field           = \n| symptoms        = \n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = \n| diagnosis       = \n| differential    = \n| prevention      = \n| treatment       = \n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n'''Autoimmune lymphoproliferative syndrome''' ('''ALPS'''), is a form of [[lymphoproliferative disorder]] (LPDs). It affects [[lymphocyte]] [[apoptosis]].<ref name=\"pmid18193364\" />\n\nIt is a rare genetic disorder of abnormal [[lymphocyte]] survival caused by defective [[Fas receptor|Fas]] mediated [[apoptosis]].<ref name=\"pmid16522544\" /> Normally, after infectious insult, the immune system down-regulates by increasing Fas expression on activated B and T lymphocytes and Fas-ligand on activated T lymphocytes. Fas and Fas-ligand interact to trigger the caspase cascade, leading to cell apoptosis. Patients with ALPS have a defect in this apoptotic pathway, leading to chronic non-malignant lymphoproliferation, autoimmune disease, and secondary cancers.<ref name=\"pmid19930184\" />\n\n==Presentation==\nAll people with ALPS have signs of lymphoproliferation, which makes it the most common clinical manifestation of the disease. The increased proliferation of lymphoid cells can cause the size of lymphoid organs such as the [[lymph node]]s and [[spleen]] to increase ([[lymphadenopathy]] and [[splenomegaly]], present in respectively over 90% and over 80% of patients). The [[liver]] is enlarged ([[hepatomegaly]] in 30 - 40% of patients).\n\nAutoimmune disease is the second most common clinical manifestation and one that most often requires treatment. Autoimmune cytopenias: Most common. Can be mild to very severe. Can be intermittent or chronic.<ref name=\"pmid15542578\" /> These include: Autoimmune [[hemolytic anemia]], Autoimmune [[neutropenia]], Autoimmune [[thrombocytopenia]].\n\nOther signs can affect organ systems similar to [[systemic lupus erythematosus]] (least common, affecting <5% of patients) Symptoms of the nervous system include: Autoimmune cerebellar [[ataxia]]; [[Guillain\u2013Barr\u00e9 syndrome]]; [[transverse myelitis]]. Gastrointestinal signs like autoimmune esophagitis, gastritis, colitis, hepatitis, [[pancreatitis]] can be found or (Dermatologic) [[Urticaria]], (Pulmonary) [[bronchiolitis obliterans]], (Renal) [[autoimmune glomerulonephritis]], [[nephrotic syndrome]].\n\nAnother sign are cancers such as [[Hodgkin's lymphoma|Hodgkin]] and [[Non-Hodgkin lymphoma|non-Hodgkin]] lymphomas which appear to be increased,<ref name=\"Straus2001\" /> possibly due to [[Epstein\u2013Barr virus]]-encoded RNA-positivity. Some carcinomas may occur. Unaffected family members with genetic mutations are also at an increased risk of developing cancer.\n\n==Genetics==\nThis condition is usually caused by mutations in the FAS gene. Rarely cases due to mutations in other genes including the \nFAS ligand gene have been reported.<ref name=Magerus-Chatinet2012>Magerus-Chatinet A, Stolzenberg MC, Lanzarotti N, Neven B, Daussy C, Picard C, Neveux N, Desai M, Rao M, Ghosh K, Madkaikar M, Fischer A, Rieux-Laucat F (2012) Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. J Allergy Clin Immunol</ref>\n\n==Diagnosis==\n{{columns-list|colwidth=30em|\n* Elevated peripheral blood Double Negative T cells (DNTs)<ref name=\"pmid12139944\" />\n** Required for diagnosis\n** Immunophenotype: CD3+/CD4-/CD8-/TCRalpha/beta+\n** Measured by [[flow cytometry]]: Normal values <2.5% total T cells; <1% of total lymphocytes in peripheral blood\n** Marked elevations >5% virtually pathognomonic for ALPS\n** Mild elevations also found in other autoimmune diseases\n** Thought to be cytotoxic T lymphocytes that have lost CD8 expression\n** Unknown if driver of disease or epiphenomenon\n** May be falsely elevated in setting of lymphopenia or falsely decreased with immunosuppressive treatment\n* Biomarkers<ref name=\"pmid19176318\" /><ref name=\"pmid20227752\" />\n** Polyclonal [[hypergammaglobulinemia]]<ref name=\"pmid20068224\" />\n** Elevated serum FASL\n** Elevated plasma [[Interleukin 10|IL-10]] and/or IL-18\n** Elevated plasma or serum [[vitamin B12]]\n* [[Autoantibodies]]: Non-specific. Can have antibodies to blood cells (DAT, anti-neutrophil, anti-platelet). Also, can have positive ANA, RF, ANCA\n* Defective in vitro Fas mediated apoptosis\n** Required for diagnosis under old definition. Now can be used to make diagnosis; however, not required to make diagnosis.\n** Time and labor-intensive assay.\n** T cells from patient and normal control supported in culture for >10 days with mitogen stimulation and IL-2 expansion and then exposed to anti-Fas IgM monoclonal antibody\n** ALPS patient T cells: Do not die with anti-Fas monoclonal antibody exposure. Normal T cells from unaffected patient do.\n** False negative in somatic Fas variant ALPS and FasL variant ALPS\n* Genetic mutations in ALPS causative genes (see below)\n}}\n===Diagnostic algorithm===\nThe old diagnostic criteria for the illness included:<ref name=\"pmid12819469\" /> Chronic non-malignant lymphoproliferation, elevated peripheral blood DNTs and defective in vitro Fas mediated apoptosis.\n\nThe new criteria<ref name=\"pmid20538792\" /> require chronic non-malignant lymphoproliferation (over six months lymphadenopathy and/or splenomegaly), elevated peripheral blood DNTs. A primary accessory in diagnosis is defective in vitro Fas mediated apoptosis and somatic or germline mutation in ALPS causative gene (FAS, FASL, CASP10).\n\nThe secondary accessory in diagnosis are elevated biomarkers (plasma sFASL over 200 pg/ml, plasma IL-10 >20 pg/ml, plasma or serum vitamin B12 >1500&nbsp;ng/L, Plasma IL-18 >500pg/ml) and immunohistochemical findings on biopsy consistent with ALPS as determined by an experienced hematopathologist. Another sign is autoimmune cytopenias and polyclonal hypergammaglobulinemia and a family history of ALPS or non-malignant lymphoproliferation.\n\nA definitive diagnosis is chronic non-malignant lymphoproliferation and/or elevated peripheral blood DNTs plus one primary accessory criterion. A probable diagnosis is the same but with one secondary accessory criterion.\n\n===Classification===\n2003 nomenclature<ref name=\"pmid12819469\" />\n* IA - [[Fas receptor|Fas]]\n* IB - [[Fas ligand]]\n* IIA - [[Caspase 10]]\n* IIB  - [[Caspase 8]]\n* III - unknown\n* IV - [[Neuroblastoma RAS viral oncogene homolog]]\n\nRevised nomenclature (2010)<ref name=\"pmid20538792\" />\n* ALPS-FAS: Fas. Germline FAS mutations. 70% of patients. Autosomal dominant. Dominant negative and haploinsufficient mutations described.<ref name=\"pmid21490157\" />\n* ALPS-sFAS: Fas. Somatic FAS mutations in DNT compartment.<ref name=\"pmid15459302\" /> 10% of patients\n* ALPS-FASL: [[Fas ligand]]. Germline FASL mutations. 3 reported cases\n* ALPS-CASP10: [[Caspase 10]]. Germline CASP10 mutation. 2% of patients\n* ALPS-U: Undefined. 20% of patients\n* CEDS: Caspase 8 deficiency state. No longer considered a subtype of ALPS but distinct disorder\n* [[RAS-associated autoimmune leukoproliferative disorder|RALD]]: [[Neuroblastoma RAS viral oncogene homolog|NRAS]], [[KRAS]]. Somatic mutations in NRAS and KRAS in lympocyte compartment. No longer considered a subtype of ALPS but distinct disesase\n\n==Treatment==\nTreatment is most commonly directed at autoimmune disease and may be needed to treat bulky lymphoproliferation. First line therapies include [[corticosteroids]] (very active but toxic with chronic use), and IVIgG, which are not as effective as in other immune cytopenia syndromes.\n\nSecond line therapies include: [[mycophenolate mofetil]] (cellcept)<ref name=\"pmid15877736\" /> which inactivates inosine monophosphate, most studied in clinical trials with responses varying (relapse, resolution, partial response). It does not affect lymphoproliferation or reduce DNTs, with no drug-drug interactions. This treatment is commonly used agent in patients who require chronic treatment based on tolerance and efficacy. It may cause hypogammaglobulinemia (transient) requiring IVIgG replacement.\n\n[[Sirolimus]] (rapamycin, rapamune) which is a mTOR ([[mammalian target of rapamycin]]) inhibitor<ref name=\"pmid16757690\" /> can be active in most patients and can in some cases lead to complete or near-complete resolution of autoimmune disease (>90%)<ref name=\"pmid19208097\" /><ref name=\"pmid19588524\" /> With this treatment most patients have complete resolution of lymphoproliferation, including lymphadenopathy and splenomegaly (>90%) and have elimination of peripheral blood DNTs. Sirolimus may not be as immune suppressive in normal lymphocytes as other agents. Some patients have had improvement in immune function with transition from cellcept to rapamycin<ref name=\"pmid21475130\" /> and it has not been reported to cause hypogammaglobulinemia. Hypothetically, Sirolimus may have lower risk of secondary cancers as opposed to other immune suppressants and requires therapeutic drug monitoring. It is the second most commonly used agent in patients that require chronic therapy. It is mostly well tolerated (though side effects include mucositis, diarrhea, hyperlipidemia, delayed wound healing) with drug-drug interactions. It has better activity against autoimmune disease and lymphoproliferation than mycophenolate mofetil and other drugs; however, sirolimus requires therapeutic drug monitoring and can cause mucositis. A risk with any agent in pre-cancerous syndrome as immune suppression can decreased tumor immunosurvellence. Its mTOR inhibitors active against lymphomas, especially EBV+ lymphomas. The Goal serum trough is 5-15&nbsp;ng/ml and can consider PCP prophylaxis but usually not needed.\n\nOther treatments may include drugs like [[Fansidar]],<ref name=\"pmid11918552\" /><ref name=\"pmid17674358\" /> mercaptopurine: More commonly used in Europe. Another is [[rituximab]] but this can cause protracted hypogammaglobulinemia<ref name=\"pmid19214977\" /> and a [[splenectomy]] but there is a >30% risk of pneumococcal sepsis even with vaccination and antibiotic prophylaxis<ref name=\"pmid21885601\" /><ref name=\"pmid21885602\" />\n\n==References==\n{{Reflist|30em|refs=\n<ref name=\"pmid18193364\">{{cite journal |pages=87\u201392 |doi=10.1007/s12026-007-8001-1 |title=The autoimmune lymphoproliferative syndrome: An experiment of nature involving lymphocyte apoptosis |year=2007 |last1=Fleisher |first1=Thomas A. |journal=Immunologic Research |volume=40 |pmid=18193364 |issue=1|url=https://zenodo.org/record/1232880 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid16522544\">{{cite journal |pages=15\u201323 |doi=10.1080/10245330500329094 |title=Causes and consequences of the autoimmune lymphoproliferative syndrome |year=2006 |last1=Rao |first1=V. Koneti |last2=Straus |first2=Stephen E. |journal=Hematology |volume=11 |pmid=16522544 |issue=1|url=https://zenodo.org/record/1234465 }}</ref> \n<ref name=\"pmid19930184\">{{cite journal |pages=205\u201316 |doi=10.1111/j.1365-2141.2009.07991.x |title=Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) |year=2010 |last1=Teachey |first1=David T. |last2=Seif |first2=Alix E. |last3=Grupp |first3=Stephan A. |journal=British Journal of Haematology |volume=148 |issue=2 |pmid=19930184 |pmc=2929682}}</ref> \n<ref name=\"pmid15542578\">{{cite journal |pages=2443\u20138 |doi=10.1182/blood-2004-09-3542 |title=Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS) |year=2005 |last1=Teachey |first1=David T. |journal=Blood |volume=105 |issue=6 |pmid=15542578 |last2=Manno |first2=Catherine S. |last3=Axsom |first3=Kelly M. |last4=Andrews |first4=Timothy |last5=Choi |first5=John K. |last6=Greenbaum |first6=Barbara H. |last7=McMann |first7=Joseph M. |last8=Sullivan |first8=Kathleen E. |last9=Travis |first9=Susan F.|last10=Grupp |first10=S. A. |display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid12139944\">{{cite journal |pages=21\u201330 |doi=10.1006/clim.2002.5225 |title=A Composite Picture of TcR\u03b1/\u03b2<sup>+</sup> CD4<sup>\u2212</sup>CD8<sup>\u2212</sup> T Cells (\u03b1/\u03b2-DNTCs) in Humans with Autoimmune Lymphoproliferative Syndrome |year=2002 |last1=Bleesing |first1=Jack J.H. |last2=Brown |first2=Margaret R. |last3=Novicio |first3=Cynthia |last4=Guarraia |first4=David |last5=Dale |first5=Janet K. |last6=Straus |first6=Stephen E. |last7=Fleisher |first7=Thomas A. |journal=Clinical Immunology |volume=104 |pmid=12139944 |issue=1}}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid19176318\">{{cite journal |pages=3027\u201330 |doi=10.1182/blood-2008-09-179630 |title=FAS-L, IL-10, and double-negative CD4<sup>\u2212</sup>CD8<sup>\u2212</sup> TCR \u03b1/\u03b2<sup>+</sup> T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function |year=2009 |last1=Magerus-Chatinet |first1=Aude |last2=Stolzenberg |first2=Marie-Claude |last3=Loffredo |first3=Maria S. |last4=Neven |first4=B\u00e9n\u00e9dicte |last5=Schaffner |first5=Catherine |last6=Ducrot |first6=Nicolas |last7=Arkwright |first7=Peter D. |last8=Bader-Meunier |first8=Brigitte |last9=Barbot |first9=Jos\u00e9 |last10=Blanche |first10=S. |last11=Casanova |first11=J.-L. |last12=Debre |first12=M. |last13=Ferster |first13=A. |last14=Fieschi |first14=C. |last15=Florkin |first15=B. |last16=Galambrun |first16=C. |last17=Hermine |first17=O. |last18=Lambotte |first18=O. |last19=Solary |first19=E. |last20=Thomas |first20=C. |last21=Le Deist |first21=F. |last22=Picard |first22=C. |last23=Fischer |first23=A. |last24=Rieux-Laucat |first24=F. |journal=Blood |volume=113 |issue=13 |pmid=19176318|display-authors=8 |url=http://bloodjournal.hematologylibrary.org/cgi/reprint/113/13/3027 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid20227752\">{{cite journal |pages=946\u2013949.e6 |doi=10.1016/j.jaci.2009.12.983 |title=Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome |year=2010 |last1=Caminha |first1=Iusta |last2=Fleisher |first2=Thomas A. |last3=Hornung |first3=Ronald L. |last4=Dale |first4=Janet K. |last5=Niemela |first5=Julie E. |last6=Price |first6=Susan |last7=Davis |first7=Joie |last8=Perkins |first8=Katie |last9=Dowdell |first9=Kennichi C. |last10=Brown |first10=Margaret R. |last11=Rao |first11=V. Koneti |last12=Oliveira |first12=Jo\u00e3o Bosco |journal=Journal of Allergy and Clinical Immunology |volume=125 |issue=4 |pmid=20227752|display-authors=8 |pmc=3412519 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid20068224\">{{cite journal |pages=2142\u20135 |doi=10.1182/blood-2009-08-239525 |title=Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: A multi-institutional study |year=2010 |last1=Seif |first1=A. E. |last2=Manno |first2=C. S. |last3=Sheen |first3=C. |last4=Grupp |first4=S. A. |last5=Teachey |first5=D. T. |journal=Blood |volume=115 |issue=11 |pmid=20068224 }}{{MEDRS|date=December 2011}}</ref> \n<ref name=\"pmid12819469\">{{cite journal |pages=417\u201321 |doi=10.1097/00002281-200307000-00008 |title=Autoimmune lymphoproliferative syndrome |year=2003 |last1=Sneller |first1=Michael C. |last2=Dale |first2=Janet K. |last3=Straus |first3=Stephen E. |journal=Current Opinion in Rheumatology |volume=15 |issue=4 |pmid=12819469|url=https://zenodo.org/record/1234778 }}</ref>\n<ref name=\"pmid20538792\">{{cite journal |pages=e35\u201340 |doi=10.1182/blood-2010-04-280347 |pmc=2953894 |title=Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH International Workshop |year=2010 |last1=Oliveira |first1=J. B. |last2=Bleesing |first2=J. J. |last3=Dianzani |first3=U. |last4=Fleisher |first4=T. A. |last5=Jaffe |first5=E. S. |last6=Lenardo |first6=M. J. |last7=Rieux-Laucat |first7=F. |last8=Siegel |first8=R. M. |last9=Su |first9=H. C. |last10=Teachey |first10=D. T. |last11=Rao |first11=V. K. |journal=Blood |volume=116 |issue=14 |pmid=20538792|display-authors=8 }}</ref>\n<ref name=\"pmid21490157\">{{cite journal |pages=6035\u201343 |doi=10.4049/jimmunol.1100021 |title=FAS Haploinsufficiency is a Common Disease Mechanism in the Human Autoimmune Lymphoproliferative Syndrome |year=2011 |last1=Kuehn |first1=H. S. |last2=Caminha |first2=I. |last3=Niemela |first3=J. E. |last4=Rao |first4=V. K. |last5=Davis |first5=J. |last6=Fleisher |first6=T. A. |last7=Oliveira |first7=J. B. |journal=The Journal of Immunology |volume=186 |issue=10 |pmid=21490157|pmc=3725553 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid15459302\">{{cite journal |pages=1409\u201318 |doi=10.1056/NEJMoa040036 |title=Autoimmune Lymphoproliferative Syndrome with SomaticFasMutations |year=2004 |last1=Holzelova |first1=Eliska |last2=Vonarbourg |first2=C\u00e9dric |last3=Stolzenberg |first3=Marie-Claude |last4=Arkwright |first4=Peter D. |last5=Selz |first5=Fran\u00e7oise |last6=Prieur |first6=Anne-Marie |last7=Blanche |first7=St\u00e9phane |last8=Bartunkova |first8=Jirina |last9=Vilmer |first9=Etienne |last10=Fischer |first10=Alain |last11=Le Deist |first11=Fran\u00e7oise |last12=Rieux-Laucat |first12=Fr\u00e9d\u00e9ric |journal=New England Journal of Medicine |volume=351 |issue=14 |pmid=15459302|display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid15877736\">{{cite journal |pages=534\u20138 |doi=10.1111/j.1365-2141.2005.05496.x |title=Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome |year=2005 |last1=Koneti Rao |first1=V. |last2=Dugan |first2=Faith |last3=Dale |first3=Janet K. |last4=Davis |first4=Joie |last5=Tretler |first5=Jean |last6=Hurley |first6=John K. |last7=Fleisher |first7=Thomas |last8=Puck |first8=Jennifer |last9=Straus |first9=Stephen E. |journal=British Journal of Haematology |volume=129 |issue=4 |pmid=15877736 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid16757690\">{{cite journal |pages=1965\u201371 |doi=10.1182/blood-2006-01-010124 |pmc=1895548 |title=Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS) |year=2006 |last1=Teachey |first1=D. T. |journal=Blood |volume=108 |issue=6 |pmid=16757690 |last2=Obzut |first2=DA |last3=Axsom |first3=K |last4=Choi |first4=JK |last5=Goldsmith |first5=KC |last6=Hall |first6=J |last7=Hulitt |first7=J |last8=Manno |first8=CS |last9=Maris |first9=JM|last10=Rhodin |first10=N |last11=Sullivan |first11=K. E. |last12=Brown |first12=V. I. |last13=Grupp |first13=S. A. |display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid19208097\">{{cite journal |pages=101\u20136 |doi=10.1111/j.1365-2141.2009.07595.x |pmc=2819393 |title=Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome |year=2009 |last1=Teachey |first1=David T. |last2=Greiner |first2=Robert |last3=Seif |first3=Alix |last4=Attiyeh |first4=Edward |last5=Bleesing |first5=Jack |last6=Choi |first6=John |last7=Manno |first7=Catherine |last8=Rappaport |first8=Eric |last9=Schwabe |first9=Dirk |last10=Sheen |first10=Cecilia |last11=Sullivan |first11=Kathleen E. |last12=Zhuang |first12=Hongming |last13=Wechsler |first13=Daniel S. |last14=Grupp |first14=Stephan A. |journal=British Journal of Haematology |volume=145 |pmid=19208097 |issue=1|display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid19588524\">{{cite journal |title=Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome |pages=1117\u20139 |year=2009 |last1=Jani\u0107 |first1=MD |last2=Brasanac |first2=CD |last3=Jankovi\u0107 |first3=JS |last4=Dokmanovi\u0107 |first4=BL |last5=Krstovski |first5=RN |last6=Kraguljac Kurtovi\u0107 |first6=JN |volume=53 |issue=6 |doi=10.1002/pbc.22151 |journal=Pediatric Blood & Cancer |pmid=19588524}}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid17674358\">{{cite journal |title=Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome |pages=1049\u201355 |pmid=17674358 |doi=10.1002/ajh.21007 |year=2007 |last1=Rao |first1=V. Koneti |last2=Dowdell |first2=Kennichi C. |last3=Dale |first3=Janet K. |last4=Dugan |first4=Faith |last5=Pesnicak |first5=Lesley |last6=Bi |first6=Lilia L. |last7=Hoffmann |first7=Victoria |last8=Penzak |first8=Scott |last9=Avila |first9=Nilo A. |last10=Fleisher |first10=Thomas A. |last11=Puck |first11=Jennifer M. |last12=Straus |first12=Stephen E. |journal=American Journal of Hematology |volume=82 |issue=12|display-authors=8 }}</ref> \n<ref name=\"pmid11918552\">{{cite journal |pages=176\u201388 |doi=10.1046/j.1365-2141.2002.03357.x |title=Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: Preliminary results of a clinical cohort study and molecular observations |year=2002 |last1=Van Der Werff Ten Bosch |first1=Jutte |last2=Schotte |first2=Peter |last3=Ferster |first3=Alice |last4=Azzi |first4=Nadira |last5=Boehler |first5=Thomas |last6=Laurey |first6=Genevieve |last7=Arola |first7=Mikko |last8=Demanet |first8=Christian |last9=Beyaert |first9=Rudi |last10=Thielemans |first10=Kris |last11=Otten |first11=Jacques |journal=British Journal of Haematology |volume=117 |pmid=11918552 |issue=1|display-authors=8 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid21475130\">{{cite journal|pmid=21475130 |year=2011 |last1=Teachey |first1=David T. |title=Autoimmune Lymphoproliferative Syndrome: New Approaches to Diagnosis and Management |volume=9 |issue=3 |pages=233\u20135 |journal=Clinical Advances in Hematology & Oncology |url=http://www.clinicaladvances.com/index.php/our_publications/hem_onc-article/1956/ |url-status=dead |archiveurl=https://web.archive.org/web/20120426050323/http://www.clinicaladvances.com/index.php/our_publications/hem_onc-article/1956/ |archivedate=2012-04-26 }}{{MEDRS|date=December 2011}}</ref>\n<ref name=\"pmid19214977\">{{cite journal |pages=847\u201352 |doi=10.1002/pbc.21965 |pmc=2774763 |title=Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS) |year=2009 |last1=Rao |first1=V. Koneti |last2=Price |first2=Susan |last3=Perkins |first3=Katie |last4=Aldridge |first4=Patricia |last5=Tretler |first5=Jean |last6=Davis |first6=Joie |last7=Dale |first7=Janet K. |last8=Gill |first8=Fred |last9=Hartman |first9=Kip R. |last10=Stork |first10=Linda C. |last11=Gnarra |first11=David J. |last12=Krishnamurti |first12=Lakshmanan |last13=Newburger |first13=Peter E. |last14=Puck |first14=Jennifer |last15=Fleisher |first15=Thomas |journal=Pediatric Blood & Cancer |volume=52 |issue=7 |pmid=19214977|display-authors=8 }}</ref>\n<ref name=\"pmid21885601\">{{cite journal |pages=5741\u201351 |doi=10.1182/blood-2011-07-325217 |pmc=3228494 |title=How I treat autoimmune lymphoproliferative syndrome |year=2011 |last1=Rao |first1=V. K. |last2=Oliveira |first2=J. B. |journal=Blood |volume=118 |issue=22 |pmid=21885601}}</ref>\n<ref name=\"pmid21885602\">{{cite journal |pages=4798\u2013807 |doi=10.1182/blood-2011-04-347641 |title=A survey of 90 patients with autoimmune lymphoproliferative syndrome related to ''TNFRSF6'' mutation |year=2011 |last1=Neven |first1=B\u00e9n\u00e9dicte |last2=Magerus-Chatinet |first2=Aude |last3=Florkin |first3=Benoit |last4=Gobert |first4=Delphine |last5=Lambotte |first5=Olivier |last6=De Somer |first6=Lien |last7=Lanzarotti |first7=Nina |last8=Stolzenberg |first8=Marie-Claude |last9=Bader-Meunier |first9=Brigitte |last10=Aladjidi |first10=N. |last11=Chantrain |first11=C. |last12=Bertrand |first12=Y. |last13=Jeziorski |first13=E. |last14=Leverger |first14=G. |last15=Michel |first15=G. |last16=Suarez |first16=F. |last17=Oksenhendler |first17=E. |last18=Hermine |first18=O. |last19=Blanche |first19=S. |last20=Picard |first20=C. |last21=Fischer |first21=A. |last22=Rieux-Laucat |first22=F. |journal=Blood |volume=118 |issue=18 |pmid=21885602|display-authors=8 }}</ref>\n}}\n== External links ==\n{{Medical resources\n| DiseasesDB      = 33425\n| ICD10           = \n| ICD9            = {{ICD9|279.41}}\n| ICDO            = \n| OMIM            = 601859\n| OMIM_mult       = {{OMIM2|603909}}\n| MedlinePlus     = \n| eMedicineSubj   = \n| eMedicineTopic  = \n| MeshID          = \n| Orphanet        = 3261\n}}\n[[Category:Lymphocytic immune system disorders]]\n[[Category:RASopathies]]\n[[Category:Syndromes with tumors]]\n", "name_user": "Rjwilmsi", "label": "safe", "comment": "Journal cites:,", "url_page": "//en.wikipedia.org/wiki/Autoimmune_lymphoproliferative_syndrome"}
{"title_page": "Bhilwara (Rajasthan Assembly constituency)", "text_new": "{{linkrot|date=April 2020}}\n\n{{Use dmy dates|date=April 2020}}\n{{Use Indian English|date=April 2020}}\n'''Bhilwara Vidhan Sabha Constituency''' is one of the 200 seats of [[Rajasthan Legislative Assembly]]. It comes under [[Bhilwara_district | Bhilwara district]]  and [[Bhilwara (Lok Sabha constituency) | Bhilwara Lok Sabha Constituency]].\n\n==Member of Legislative Assembly==\n{| class=\"wikitable\" width=80%\n|-\n! style=\"background-color:#666666; color:white\" colspan=\"2\"|Year\n! style=\"background-color:#666666; color:white\"|Member\n! style=\"background-color:#666666; color:white\"|Political Party\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1951 || Tej Mal  || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1957 || Kamla Bai  || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1962 || Nirmala Devi || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1967 || R.P. Lacha  || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1972 || Bhauwat Lal Bhadada  || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Janata Party/meta/color}}\" |\n|| 1977 ||  Kaushal Kishore Jain || [[Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 1980 || Bansilal Patwa  || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1985 ||  Pranvir || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 1990 ||  Bansilal Patwa || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 1993 ||  Jagdish Chandra Darak || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 1998 || Ramrichpal Nuwal || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 2003 || Devendra Singh || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 2005 || [[Subhash Chandra Baheria]] || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 2008 || [[Vitthal Shankar Avasthi]] || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 2013 || [[Vitthal Shankar Avasthi]] || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 2018 || [[Vitthal Shankar Avasthi]] || [[Bharatiya Janata Party]]\n|-\n|}\n\n==References==\n*http://www.elections.in/rajasthan/assembly-constituencies/bhilwara.html\n*https://rajassembly.nic.in/MemberConstituencyWise.aspx\n\n\n[[Category:Assembly constituencies of Rajasthan]]\n[[Category:Bhilwara district]]\n\n\n{{India-election-stub}}\n", "text_old": "{{linkrot|date=April 2020}}\n\n{{Use dmy dates|date=April 2020}}\n{{Use Indian English|date=April 2020}}\n'''Bhilwara Vidhan Sabha Constituency''' is one of the 200 seats of [[Rajasthan Legislative Assembly]]. It comes under [[Bhilwara_district | Bhilwara district]]  and [[Bhilwara (Lok Sabha constituency) | Bhilwara Lok Sabha Constituency]].\n\n==Member of Legislative Assembly==\n{| class=\"wikitable\" width=80%\n|-\n! style=\"background-color:#666666; color:white\" colspan=\"2\"|Year\n! style=\"background-color:#666666; color:white\"|Member\n! style=\"background-color:#666666; color:white\"|Political Party\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1951 || Tej Mal  || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1957 || Kamla Bai  || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1962 || Nirmala Devi || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1967 || R.P. Lacha  || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1972 || Bhauwat Lal Bhadada  || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Janata Party/meta/color}}\" |\n|| 1977 ||  Kaushal Kishore Jain || [[Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 1980 || Bansilal Patwa  || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 1985 ||  Pranvir || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 1990 ||  Bansilal Patwa || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 1993 ||  Jagdish Chandra Darak || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 1998 || Ramrichpal Nuwal || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Indian National Congress/meta/color}}\" |\n|| 2003 || Devendra Singh || [[Indian National Congress]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 2005 || [[Subhash Chandra Baheria]] || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 2008 || [[Vitthal Shankar Avasthi]] || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 2013 || [[Vitthal Shankar Avasthi]] || [[Bharatiya Janata Party]]\n|-\n|style=\"background-color: {{Bharatiya Janata Party/meta/color}}\" |\n|| 2018 || [[Vitthal Shankar Avasthi]] || [[Bharatiya Janata Party]]\n|-\n|}\n\n==References==\n*http://www.elections.in/rajasthan/assembly-constituencies/bhilwara.html\n*https://rajassembly.nic.in/MemberConstituencyWise.aspx\n\n\n[[Category:Assembly constituencies of Rajasthan]]\n[[Category:Bhilwara district]]\n", "name_user": "Rosguill", "label": "safe", "comment": "+{{India-election-stub}} usingStubSorter", "url_page": "//en.wikipedia.org/wiki/Bhilwara_(Rajasthan_Assembly_constituency)"}
{"title_page": "Tim Rollinson", "text_new": "{{Use dmy dates|date=October 2016}}\n{{Use Australian English|date=October 2016}}\n{{Infobox musical artist <!-- For individuals; see Wikipedia:WikiProject_Musicians -->\n| name                = Tim Rollinson\n| image                 = \n| alt             = \n| caption            = \n| background          = non_vocal_instrumentalist\n| birth_name          = Timothy Robert Rollinson\n| alias               = \n| birth_date          = {{Birth year and age|1959}}\n| death_date          = <!-- {{Death date and age|YYYY|MM|DD|YYYY|MM|DD|df=y}} (death date then birth) -->\n| origin              = [[Bolton, England|Bolton]], England\n| instrument          = [[guitar]]\n| genre               = [[jazz music|jazz]]\n| occupation          = musician, songwriter\n| years_active        = 1979\u2013present\n| label               = ID, [[Mercury Records|Mercury]], Rufus/UMA\n| associated_acts     = [[Directions in Groove]], [[The Blackeyed Susans]], [[Vince Jones]]\n| website             = [http://www.timrollinson.com/ timrollinson.com]\n}}\n'''Timothy Robert \"Tim\" Rollinson''' (born 1959) from [[Bolton, England]] is an Australian [[jazz music|jazz]] guitarist and composer who was a founder of [[Sydney]]-based [[acid jazz]] group [[Directions in Groove]] (D.I.G.) (1991\u20131998, 2008) as well as his own trio, quartets and studio project, The Modern Congress. His work for D.I.G. included winning two [[APRA Awards (Australia)|APRA Awards]] for song writing, 1994 'Best Jazz Composition' for \"Favourite\" and 1996 'Most Performed Jazz Work' for \"Futures\". As well as two [[ARIA Music Award]] nominations, [[ARIA Music Awards of 1994|1994]] 'Breakthrough Artist \u2013 Single' for \"Re-Invent Yourself\" and [[ARIA Music Awards of 1995|1995]] 'Breakthrough Artist \u2013 Album' for ''Deeper''. He released two solo albums, ''Cause and Effect'' in 1997 and ''You Tunes'' in 2010.\n\n==Biography==\nTimothy Robert Rollinson was born in 1959 in [[Bolton, England]]. He joined cabaret band Pressed Meat & the Smallgoods in Sydney in mid-1989 on guitar which included [[Kathy Wemyss]] (ex-[[Chad's Tree]]).<ref name=\"McFDIG\"/> Both were recruited to perform and record with [[The Blackeyed Susans]] from late 1990 to early 1991. That group had formed in [[Perth, Western Australia]] in 1989 and relocated to Sydney and collected new members.\n\nIn 1991 Rollinson was the founding guitarist for [[acid jazz]] group [[Directions in Groove]] (D.I.G.).<ref name=\"McFDIG\"/> He contributed song writing to the group's three albums.<ref name=\"ASCAP\"/> Rollinson released a solo album, ''Cause and Effect'' in 1997 on [[Mercury Records]]. The third album for D.I.G., ''Curvystrasse'', followed in 1998 and the group disbanded thereafter.<ref name=\"McFDIG\"/> They briefly reformed in 2008 for the Remixed Live Tour.<ref name=\"Winterford\"/> His work for D.I.G. included winning two [[APRA Awards (Australia)|APRA Awards]] for song writing, 1994 'Best Jazz Composition' for \"Favourite\" and 1996 'Most Performed Jazz Work' for \"Futures\".<ref name=\"APRAWin1994\"/><ref name=\"APRAWin1996\"/> As well as two [[ARIA Music Award]] nominations, [[ARIA Music Awards of 1994|1994]] 'Breakthrough Artist \u2013 Single' for \"Re-Invent Yourself\" and [[ARIA Music Awards of 1995|1995]] 'Breakthrough Artist \u2013 Album' for ''Deeper''.<ref name=\"ARIAList\"/>\n\nRollinson has performed with [[Vince Jones]], [[Louis Tillett]], [[Tim Hopkins]], [[Tony Buck (musician)|Tony Buck]], [[Joe Lane (singer)|Joe Lane]], [[Barney McAll]] and [[David Watson (musician)|David Watson]].\n\nRollinson has written music for theatre, short films, two features and for television. He released his second solo album, ''You Tunes'', on Rufus Records in June 2010.<ref name=\"YouTunes\"/>\n\n==Discography==\n\n===Albums===\n;Band member, solo projects\n{| class=\"wikitable\"\n|-\n! Year !! Title !! Artist !! Label !! Details\n|-\n| 1992 || ''Directions in Groove'' || [[Directions in Groove|D.I.G. (Directions in Groove)]] || ID 0009-2 || \n|-\n| rowspan=\"2\"|1995 || ''Deeper'' || D.I.G. || Verve/ID 5 186092 || March 1995\n|-\n| ''Speakeasy'' || D.I.G. || Verve Forecast 5285392 || June 1995\n|-\n| 1996 || ''Crime'' || D.I.G. || Verve Forecast 852942 || \n|-\n| 1997 || ''Cause and Effect'' || Tim Rollinson || [[Mercury Records]] 5329072 || \n|-\n| 1998 || ''Curvystrasse'' || D.I.G. || EMI 97196 || September 1998\n|-\n| 2003 || ''D.I.G. Live'' || D.I.G. || Watt003 || Live at Milton Theatre and The Basement in January 1999\n|-\n| 2005 || ''The Hidden Soul of Harmony'' || The Modern Congress || CDD006 || \n|-\n| 2010 || ''You Tunes'' || Tim Rollinson || Rufus Records/UMA || 1 June 2010\n|-\n| 2016 || ''Nitty Gritty'' || Tim Rollinson || || \n|-\n| 2019 || ''Old New Blues'' || Tim Rollinson || ||\n|}\n\n;Guest musician\n*''[[Anchor Me (The Blackeyed Susans song)|Anchor Me]]'' (EP)&nbsp;\u2013 [[The Blackeyed Susans]] (March 1991, Waterfront Records)\n* 1991    Peter Dasent  Dir: Peter Jackson   Meet The Feebles  Q.D.K Media\n* 1991    Grant McLennan (Go-Betweens)   Watershed          White Label\n*''[[Welcome Stranger (The Blackeyed Susans album)|Welcome Stranger]]''&nbsp;\u2013 The Blackeyed Susans (August 1992, Waterfront)\n* 1992    Caroline Loftus                               Sugar                 Larrikin\n* 1993    [[Ian Cooper (Violinist)|Ian Cooper]]                                     Soundpost         Larrikin\n* 1994    Tim Hopkins                                   Pandora\u2019s Box   ABC\n* 1994    Peggy Van Zalm                            Shine / Soul Magic\n* 1997    Zeek\u2019s Beek                                   Zeek\u2019s Beek       ABC Jazz\n* 2004    Inga Liljestrom                               Elk\n* 2007    Steve Morrison and Jeff Duff         So Quiet\n* 2007    Dave Mason (The Reels)              Reelsville\n* 2007    Betty Vale                                      Red\n* 2009    Steve Morrison                              Live at the Basement\n*2009    Gerard Masters                             Spin (EP)\n\n===Compilation albums===\n*2005     Australia Select  3                          National Gallery Of Victoria\n*2005     Lazy Days & Sundays 2                 Instinctive Travels\n*2005     Bondi Calling 3                               Vitamin\n*2005     Vine Time                                        Instinctive Travels\n*2005     Mi Casa Tu Casa                            Casa Del Discos\n*2001     State Of The Union                         EMF          (US release)\n*1998     Groove Hip Hop                              Blue Note\n*1995     The Soul Of Jazz Volume 3            Verve         (Europe)\n*1993     Triple J Live At The Wireless 3      ABC\n*1991     Triple J Live At The Wireless         Mushroom\n\n==References==\n{{refbegin}}\n;General\n* {{cite encyclopedia |last=McFarlane |first=Ian |authorlink=Ian McFarlane |encyclopedia=[[Encyclopedia of Australian Rock and Pop]] |title=Whammo Homepage |url=//www.whammo.com.au/index.asp |accessdate=1 June 2010 |year=1999 |publisher=[[Allen & Unwin]] |location=[[St Leonards, New South Wales|St Leonards, NSW]] |isbn=1-86508-072-1 |url-status=dead |archiveurl=https://web.archive.org/web/20040405231007/http://www.whammo.com.au/index.asp |archivedate=5 April 2004 |df=dmy-all }} Note: Archived [on-line] copy has limited functionality.\n;Specific\n{{refend}}\n{{Reflist|colwidth=25em|refs=\n\n<ref name=\"ASCAP\">{{cite web | url = http://www.ascap.com/ace/search.cfm?requesttimeout=300&mode=results&searchstr=1544131&search_in=c&search_type=exact&search_det=t,s,w,p,b,v&results_pp=20&start=1 | title = ASCAP ACE - Search Results for \"Rollinson Timothy Robert\" | publisher = [[American Society of Composers, Authors and Publishers]] (ASCAP) | accessdate = 1 June 2010}} Note: displays 10 results.</ref>\n\n<ref name=\"McFDIG\">McFarlane [https://web.archive.org/web/20040831114938/http://www.whammo.com.au/encyclopedia.asp?articleid=280 'd.i.g. (directions in groove)'] entry. Retrieved 1 June 2010.</ref>\n\n<ref name=\"Winterford\">{{cite news | url = http://www.jazzmusic.com.au/jazz-music-articles/2008/6/20/acid-jazz-flashback/ | title = Acid Jazz Flashback | newspaper = [[The Sydney Morning Herald]] | publisher = [[Fairfax Media]] | last = Winterford | first = Brett | date = 20 June 2008 | accessdate = 1 June 2010 }}</ref>\n\n<ref name=\"APRAWin1994\">{{cite web | url = http://www.apra-amcos.com.au/APRAAwards/MusicAwards/History/1994Winners.aspx | title = 1994 Winners - APRA Music Awards | publisher = [[Australasian Performing Right Association]] (APRA) | accessdate = 2 June 2010 }}</ref>\n\n<ref name=\"APRAWin1996\">{{cite web | url = http://www.apra-amcos.com.au/APRAAwards/MusicAwards/History/1996Winners.aspx | title = 1996 Winners - APRA Music Awards | publisher = Australasian Performing Right Association (APRA) | accessdate = 2 June 2010 }}</ref>\n\n<ref name=\"ARIAList\">{{cite web | url = http://www.ariaawards.com.au/history-by-artist.php?letter=D&artist=D.I.G. | title = ARIA Awards 2009 : History: Winners by Artist: D.I.G. | publisher = [[Australian Recording Industry Association]] (ARIA) | accessdate = 2 June 2010}}</ref>\n\n<ref name=\"YouTunes\">{{cite web | url = http://eastsidefm.org/2010/06/tim-rollinson-album-launch-you-tunes-sydney-nsw-210610/ | title = Gig guide >> Tim Rollinson album launch: \\''You Tunes''\\ Sydney, NSW - 21/06/10 | publisher = Eastside Radio (Radio Eastern Sydney Co-operative Ltd) | date= 1 June 2010 | accessdate = 2 June 2010}}</ref>\n\n}}\n\n==External links==\n*{{Official website|http://www.timrollinson.com/}}\n*{{MusicBrainz artist|id=906ccd59-1528-46a2-8db4-ddd0d0c913fe}}\n\n{{Authority control}}\n\n{{DEFAULTSORT:Rollinson, Tim}}\n[[Category:1959 births]]\n[[Category:Australian jazz guitarists]]\n[[Category:Living people]]\n[[Category:Directions in Groove members]]\n", "text_old": "{{Use dmy dates|date=October 2016}}\n{{Use Australian English|date=October 2016}}\n{{Infobox musical artist <!-- For individuals; see Wikipedia:WikiProject_Musicians -->\n| name                = Tim Rollinson\n| image                 = \n| alt             = \n| caption            = \n| background          = non_vocal_instrumentalist\n| birth_name          = Timothy Robert Rollinson\n| alias               = \n| birth_date          = {{Birth year and age|1959}}\n| death_date          = <!-- {{Death date and age|YYYY|MM|DD|YYYY|MM|DD|df=y}} (death date then birth) -->\n| origin              = [[Bolton, England|Bolton]], England\n| instrument          = [[guitar]]\n| genre               = [[jazz music|jazz]]\n| occupation          = musician, songwriter\n| years_active        = 1979\u2013present\n| label               = ID, [[Mercury Records|Mercury]], Rufus/UMA\n| associated_acts     = [[Directions in Groove]], [[The Blackeyed Susans]], [[Vince Jones]]\n| website             = [http://www.timrollinson.com/ timrollinson.com]\n}}\n'''Timothy Robert \"Tim\" Rollinson''' (born 1959) from [[Bolton, England]] is an Australian [[jazz music|jazz]] guitarist and composer who was a founder of [[Sydney]]-based [[acid jazz]] group [[Directions in Groove]] (D.I.G.) (1991\u20131998, 2008) as well as his own trio, quartets and studio project, The Modern Congress. His work for D.I.G. included winning two [[APRA Awards (Australia)|APRA Awards]] for song writing, 1994 'Best Jazz Composition' for \"Favourite\" and 1996 'Most Performed Jazz Work' for \"Futures\". As well as two [[ARIA Music Award]] nominations, [[ARIA Music Awards of 1994|1994]] 'Breakthrough Artist \u2013 Single' for \"Re-Invent Yourself\" and [[ARIA Music Awards of 1995|1995]] 'Breakthrough Artist \u2013 Album' for ''Deeper''. He released two solo albums, ''Cause and Effect'' in 1997 and ''You Tunes'' in 2010.\n\n==Biography==\nTimothy Robert Rollinson was born in 1959 in [[Bolton, England]]. He joined cabaret band Pressed Meat & the Smallgoods in Sydney in mid-1989 on guitar which included [[Kathy Wemyss]] (ex-[[Chad's Tree]]).<ref name=\"McFDIG\"/> Both were recruited to perform and record with [[The Blackeyed Susans]] from late 1990 to early 1991. That group had formed in [[Perth, Western Australia]] in 1989 and relocated to Sydney and collected new members.\n\nIn 1991 Rollinson was the founding guitarist for [[acid jazz]] group [[Directions in Groove]] (D.I.G.).<ref name=\"McFDIG\"/> He contributed song writing to the group's three albums.<ref name=\"ASCAP\"/> Rollinson released a solo album, ''Cause and Effect'' in 1997 on [[Mercury Records]]. The third album for D.I.G., ''Curvystrasse'', followed in 1998 and the group disbanded thereafter.<ref name=\"McFDIG\"/> They briefly reformed in 2008 for the Remixed Live Tour.<ref name=\"Winterford\"/> His work for D.I.G. included winning two [[APRA Awards (Australia)|APRA Awards]] for song writing, 1994 'Best Jazz Composition' for \"Favourite\" and 1996 'Most Performed Jazz Work' for \"Futures\".<ref name=\"APRAWin1994\"/><ref name=\"APRAWin1996\"/> As well as two [[ARIA Music Award]] nominations, [[ARIA Music Awards of 1994|1994]] 'Breakthrough Artist \u2013 Single' for \"Re-Invent Yourself\" and [[ARIA Music Awards of 1995|1995]] 'Breakthrough Artist \u2013 Album' for ''Deeper''.<ref name=\"ARIAList\"/>\n\nRollinson has performed with [[Vince Jones]], [[Louis Tillett]], [[Tim Hopkins]], [[Tony Buck (musician)|Tony Buck]], [[Joe Lane (singer)|Joe Lane]], [[Barney McAll]] and [[David Watson (musician)|David Watson]].\n\nRollinson has written music for theatre, short films, two features and for television. He released his second solo album, ''You Tunes'', on Rufus Records in June 2010.<ref name=\"YouTunes\"/>\n\n==Discography==\n\n===Albums===\n;Band member, solo projects\n{| class=\"wikitable\"\n|-\n! Year !! Title !! Artist !! Label !! Details\n|-\n| 1992 || ''Directions in Groove'' || [[Directions in Groove|D.I.G. (Directions in Groove)]] || ID 0009-2 || \n|-\n| rowspan=\"2\"|1995 || ''Deeper'' || D.I.G. || Verve/ID 5 186092 || March 1995\n|-\n| ''Speakeasy'' || D.I.G. || Verve Forecast 5285392 || June 1995\n|-\n| 1996 || ''Crime'' || D.I.G. || Verve Forecast 852942 || \n|-\n| 1997 || ''Cause and Effect'' || Tim Rollinson || [[Mercury Records]] 5329072 || \n|-\n| 1998 || ''Curvystrasse'' || D.I.G. || EMI 97196 || September 1998\n|-\n| 2003 || ''D.I.G. Live'' || D.I.G. || Watt003 || Live at Milton Theatre and The Basement in January 1999\n|-\n| 2005 || ''The Hidden Soul of Harmony'' || The Modern Congress || CDD006 || \n|-\n| 2010 || ''You Tunes'' || Tim Rollinson || Rufus Records/UMA || 1 June 2010\n|-\n| 2016 || ''Nitty Gritty'' || Tim Rollinson || || \n|-\n| 2019 || ''Old New Blues'' || Tim Rollinson || ||\n|-\n|}\n\n;Guest musician\n*''[[Anchor Me (The Blackeyed Susans song)|Anchor Me]]'' (EP)&nbsp;\u2013 [[The Blackeyed Susans]] (March 1991, Waterfront Records)\n* 1991    Peter Dasent  Dir: Peter Jackson   Meet The Feebles  Q.D.K Media\n* 1991    Grant McLennan (Go-Betweens)   Watershed          White Label\n*''[[Welcome Stranger (The Blackeyed Susans album)|Welcome Stranger]]''&nbsp;\u2013 The Blackeyed Susans (August 1992, Waterfront)\n* 1992    Caroline Loftus                               Sugar                 Larrikin\n* 1993    [[Ian Cooper (Violinist)|Ian Cooper]]                                     Soundpost         Larrikin\n* 1994    Tim Hopkins                                   Pandora\u2019s Box   ABC\n* 1994    Peggy Van Zalm                            Shine / Soul Magic\n* 1997    Zeek\u2019s Beek                                   Zeek\u2019s Beek       ABC Jazz\n* 2004    Inga Liljestrom                               Elk\n* 2007    Steve Morrison and Jeff Duff         So Quiet\n* 2007    Dave Mason (The Reels)              Reelsville\n* 2007    Betty Vale                                      Red\n* 2009    Steve Morrison                              Live at the Basement\n*2009    Gerard Masters                             Spin (EP)\n\n===Compilation albums===\n*2005     Australia Select  3                          National Gallery Of Victoria\n*2005     Lazy Days & Sundays 2                 Instinctive Travels\n*2005     Bondi Calling 3                               Vitamin\n*2005     Vine Time                                        Instinctive Travels\n*2005     Mi Casa Tu Casa                            Casa Del Discos\n*2001     State Of The Union                         EMF          (US release)\n*1998     Groove Hip Hop                              Blue Note\n*1995     The Soul Of Jazz Volume 3            Verve         (Europe)\n*1993     Triple J Live At The Wireless 3      ABC\n*1991     Triple J Live At The Wireless         Mushroom\n\n==References==\n{{refbegin}}\n;General\n* {{cite encyclopedia |last=McFarlane |first=Ian |authorlink=Ian McFarlane |encyclopedia=[[Encyclopedia of Australian Rock and Pop]] |title=Whammo Homepage |url=//www.whammo.com.au/index.asp |accessdate=1 June 2010 |year=1999 |publisher=[[Allen & Unwin]] |location=[[St Leonards, New South Wales|St Leonards, NSW]] |isbn=1-86508-072-1 |url-status=dead |archiveurl=https://web.archive.org/web/20040405231007/http://www.whammo.com.au/index.asp |archivedate=5 April 2004 |df=dmy-all }} Note: Archived [on-line] copy has limited functionality.\n;Specific\n{{refend}}\n{{Reflist|colwidth=25em|refs=\n\n<ref name=\"ASCAP\">{{cite web | url = http://www.ascap.com/ace/search.cfm?requesttimeout=300&mode=results&searchstr=1544131&search_in=c&search_type=exact&search_det=t,s,w,p,b,v&results_pp=20&start=1 | title = ASCAP ACE - Search Results for \"Rollinson Timothy Robert\" | publisher = [[American Society of Composers, Authors and Publishers]] (ASCAP) | accessdate = 1 June 2010}} Note: displays 10 results.</ref>\n\n<ref name=\"McFDIG\">McFarlane [https://web.archive.org/web/20040831114938/http://www.whammo.com.au/encyclopedia.asp?articleid=280 'd.i.g. (directions in groove)'] entry. Retrieved 1 June 2010.</ref>\n\n<ref name=\"Winterford\">{{cite news | url = http://www.jazzmusic.com.au/jazz-music-articles/2008/6/20/acid-jazz-flashback/ | title = Acid Jazz Flashback | newspaper = [[The Sydney Morning Herald]] | publisher = [[Fairfax Media]] | last = Winterford | first = Brett | date = 20 June 2008 | accessdate = 1 June 2010 }}</ref>\n\n<ref name=\"APRAWin1994\">{{cite web | url = http://www.apra-amcos.com.au/APRAAwards/MusicAwards/History/1994Winners.aspx | title = 1994 Winners - APRA Music Awards | publisher = [[Australasian Performing Right Association]] (APRA) | accessdate = 2 June 2010 }}</ref>\n\n<ref name=\"APRAWin1996\">{{cite web | url = http://www.apra-amcos.com.au/APRAAwards/MusicAwards/History/1996Winners.aspx | title = 1996 Winners - APRA Music Awards | publisher = Australasian Performing Right Association (APRA) | accessdate = 2 June 2010 }}</ref>\n\n<ref name=\"ARIAList\">{{cite web | url = http://www.ariaawards.com.au/history-by-artist.php?letter=D&artist=D.I.G. | title = ARIA Awards 2009 : History: Winners by Artist: D.I.G. | publisher = [[Australian Recording Industry Association]] (ARIA) | accessdate = 2 June 2010}}</ref>\n\n<ref name=\"YouTunes\">{{cite web | url = http://eastsidefm.org/2010/06/tim-rollinson-album-launch-you-tunes-sydney-nsw-210610/ | title = Gig guide >> Tim Rollinson album launch: \\''You Tunes''\\ Sydney, NSW - 21/06/10 | publisher = Eastside Radio (Radio Eastern Sydney Co-operative Ltd) | date= 1 June 2010 | accessdate = 2 June 2010}}</ref>\n\n}}\n\n==External links==\n*{{Official website|http://www.timrollinson.com/}}\n*{{MusicBrainz artist|id=906ccd59-1528-46a2-8db4-ddd0d0c913fe}}\n\n{{Authority control}}\n\n{{DEFAULTSORT:Rollinson, Tim}}\n[[Category:1959 births]]\n[[Category:Australian jazz guitarists]]\n[[Category:Living people]]\n[[Category:Directions in Groove members]]\n", "name_user": "Vmavanti", "label": "safe", "comment": "Applying general fixes for links, HTML, and/or references", "url_page": "//en.wikipedia.org/wiki/Tim_Rollinson"}
{"title_page": "Muff (handwarmer)", "text_new": "[[File:Francesc Masriera - Winter 1882 - Google Art Project.jpg|thumb|''Winter 1882'', by [[Francesc Masriera]].]]\nA '''muff''' is a fashion accessory for outdoors usually made of a cylinder of [[fur]] or [[fabric]] with both ends open for keeping the hands warm. It was introduced to women's fashion in the 16th century and was popular with both men and women in the 17th and 18th centuries.  By the early 20th century, muffs were used in England only by women.{{sfn|Chisholm|1911|p=955}} It is also reported that the fashion largely fell out of style in the 19th century. \n\nIt briefly returned in the mid 1940s,<ref>[http://wearinghistory.clothing/e-pattern-1940s-beret-hat-and-muff-bag/ E-PATTERN - 1940s Beret Hat and Muff Bag] Wearing History, Retrieved 8 January 2019</ref>\nand was also developed as a [[motorcycle accessory]] for attachment as rider-protection and comfort during the cooler months.\n\n==History==\nIn Roman times, the place of the glove was taken by long sleeves (''manicae'') reaching to the hand, and in winter special sleeves of fur were worn. In Medieval Latin we find the word ''muffulae'', defined by Du Cange as ''chirothecae pellitae et hibernae'' (\"leather winter gloves\"). He quotes from a [[cartulary]] of the year 817, of the issuing to monks of [[sheepskin]] coverings to be used during the winter. These may have been, as the Roman certainly were, separate coverings for each hand, although the cartulary cited also distinguishes the glove for summer from the muffulae for winter wear. The [[Old French]] ''moufle'' meant a thick glove or mitten, and from this the [[Dutch language|Dutch]] ''mof'', [[Walloon language|Walloon]] ''mouffe'', and thence [[English language|English]] \"muff\", are probably derived.{{sfn|Chisholm|1911|p=955}}\n\n==Modern usage==\nHandlebar muffs are a utility product for motorcycles and scooters to provide increased comfort in adverse weather conditions, to protect the rider from rain and [[wind chill]]. With UK commercial-availability in the early 1960s,<ref name=\"Motor Cycle 1962\"/> they are still available in three variations from a UK merchandiser of motorcycle accessories, including dedicated-types for small motorscooters.<ref name=\"Oxford\"/>\n\nTraditionally made from waterproof [[faux leather]] and lined for insulation, more-modern, [[textile]]-based materials are also used.<ref name=\"Motor Cycle 1962\"/><ref name=\"Oxford\"/>\n\nWhen reviewing clothing and riding accessories in a 1966 feature entitled \"Tough Weather Gear\" for the weekly journal [[The Motor Cycle (magazine)|''Motor Cycle'']], regular journalist John Ebbrell described the muffs as:<blockquote>''Ugly as sin they may be\u2014but there's nothing more cosier to the fingertips than a pair of handlebar muffs...Material is waterproof plasticized fabric, lined. Fitted in a jiffy, the muffs are sold through Pride and Clarke's and cost 17s 6d.<ref>[[The Motor Cycle|''Motor Cycle'']], 13 January 1966, ''Equipment for winter riding - Tough Weather Gear'' by John Ebrell, pp.32-34. Accessed 1 December 2017</ref><ref>Pride and Clarke, ''Car and Motorcycle Accessory Catalogue'', undated, p.4 Accessed 1 December 2017</ref></blockquote>\n\nWriting at his website in December 2010, American motorcycle design innovator [[Craig Vetter]] claimed to have \"created and developed\" from 1971 what he called ''Hippo Hands'', later sold to the public from 1973 by the Vetter organisation.<ref>[https://web.archive.org/web/20170501140352/http://www.craigvetter.com/pages/motorcycle_designs/Hippo-Hands-pages/Hippo-Hands-Main-page.html Hippo Hands (Archived from the original at craigvetter.com)], Archived 1 May 2017, Retrieved 1 December 2017</ref><ref name=\"MCS March 1981 a\">''Motorcycle Sport'', March 1981, p.159 (pp.146-149, 159). Ninety Eight Point Four: Keeping warm on a motorcycle in winter. ''\"A more refined (perhaps the best) handlebar muff is the Hippo-Hands, available from CTA, Unit 30E, 142A Virginia Street, Southport, Lancashire''\". Accessed 6 April 2020</ref> These were very similar to a product that was easily available to UK motorcyclists from retail shops/mail order outlets from 1957,<ref name=\"Motor Cycle 1957\">''[[The Motor Cycle]]'', 7 March 1957, p.35. ''Claude Rye'' part-page advert ''NEW HANDLEBAR MUFFS Superior black waterproof leathercloth Handlebar Muffs, lined fleece, keep hands warm and dry. Pair 10/6. Deluxe pair 11/9, Post & Pkg. 1/6 M.P.C. Plastic 29/11 pair. P & P. 2/-.'' Accessed 12 September 2019</ref> with the description ''handlebar muffs''.<ref name=\"Motor Cycle 1962\">''[[The Motor Cycle]]'', 4 October 1962, ''Pride and Clarke'' single-page advert ''Special Offer - Handlebar muffs 12/6, postage 2/6'', p.31 Accessed 1 December 2017</ref><ref>[[The Motor Cycle|''Motor Cycle'']], 21 February 1963, ''Pride and Clarke'' double-page advert ''Handlebar muffs 17/6, postage 2/6'', pp.23-24 Accessed 1 December 2017</ref><ref>[[The Motor Cycle|''Motor Cycle'']], 21 February 1963, ''You say this'' reader's letters \"''Heated Muffs Experiment''\", p.230 Accessed 1 December 2017</ref><ref>[[The Motor Cycle|''Motor Cycle'']], 4 November 1965, ''Pride and Clarke'' double-page advert, ''Handlebar muffs 17/6, postage 3/0'', p.18 Accessed 1 December 2017</ref><ref name=\"Oxford\">[http://www.oxfordproducts.com/motorcycle/product_type/accessories/handlebar_accessories/muffs/ ''Muffs''], Oxford Products, Retrieved 1 December 2017</ref><ref name=\"MCS March 1981 b\">''Motorcycle Sport'', March 1981, p.149 (pp.146-149), 159. Ninety Eight Point Four: Keeping warm on a motorcycle in winter. Accessed 6 April 2020 </ref>\n\n==Notes==\n{{reflist}}\n\n==References==\n*{{EB1911|wstitle=Muff|volume=18|page=955}}\n{{commons category|Muffs}}\n\n{{Historical clothing}}\n{{Clothing}}\n\n{{DEFAULTSORT:Muff (Handwarmer)}}\n\n[[Category:Fashion accessories]]\n[[Category:Fur]]\n[[Category:Armwear]]\n", "text_old": "[[File:Francesc Masriera - Winter 1882 - Google Art Project.jpg|thumb|''Winter 1882'', by [[Francesc Masriera]].]]\nA '''muff''' is a fashion accessory for outdoors usually made of a cylinder of [[fur]] or [[fabric]] with both ends open for keeping the hands warm. It was introduced to women's fashion in the 16th century and was popular with both men and women in the 17th and 18th centuries.  By the early 20th century, muffs were used in England only by women.{{sfn|Chisholm|1911|p=955}} It is also reported that the fashion largely fell out of style in the 19th century. \n\nIt briefly returned in the mid 1940s,<ref>[http://wearinghistory.clothing/e-pattern-1940s-beret-hat-and-muff-bag/ E-PATTERN - 1940s Beret Hat and Muff Bag] Wearing History, Retrieved 8 January 2019</ref>\nand was also developed as a [[motorcycle accessory]] for attachment as rider-protection and comfort during the cooler months.\n\n==History==\nIn Roman times, the place of the glove was taken by long sleeves (''manicae'') reaching to the hand, and in winter special sleeves of fur were worn. In Medieval Latin we find the word ''muffulae'', defined by Du Cange as ''chirothecae pellitae et hibernae'' (\"leather winter gloves\"). He quotes from a [[cartulary]] of the year 817, of the issuing to monks of [[sheepskin]] coverings to be used during the winter. These may have been, as the Roman certainly were, separate coverings for each hand, although the cartulary cited also distinguishes the glove for summer from the muffulae for winter wear. The [[Old French]] ''moufle'' meant a thick glove or mitten, and from this the [[Dutch language|Dutch]] ''mof'', [[Walloon language|Walloon]] ''mouffe'', and thence [[English language|English]] \"muff\", are probably derived.{{sfn|Chisholm|1911|p=955}}\n\n==Modern usage==\nHandlebar muffs are a utility product for motorcycles and scooters to provide increased comfort in adverse weather conditions, to protect the rider from rain and [[wind chill]]. With UK commercial-availability in the early 1960s,<ref name=\"Motor Cycle 1962\"/> they are still available in three variations from a UK merchandiser of motorcycle accessories, including dedicated-types for small motorscooters.<ref name=\"Oxford\"/>\n\nTraditionally made from waterproof [[faux leather]] and lined for insulation, more-modern, [[textile]]-based materials are also used.<ref name=\"Motor Cycle 1962\"/><ref name=\"Oxford\"/>\n\nWhen reviewing clothing and riding accessories in a 1966 feature entitled \"Tough Weather Gear\" for the weekly journal [[The Motor Cycle (magazine)|''Motor Cycle'']], regular journalist John Ebbrell described the muffs as:<blockquote>''Ugly as sin they may be\u2014but there's nothing more cosier to the fingertips than a pair of handlebar muffs...Material is waterproof plasticized fabric, lined. Fitted in a jiffy, the muffs are sold through Pride and Clarke's and cost 17s 6d.<ref>[[The Motor Cycle|''Motor Cycle'']], 13 January 1966, ''Equipment for winter riding - Tough Weather Gear'' by John Ebrell, pp.32-34. Accessed 1 December 2017</ref><ref>Pride and Clarke, ''Car and Motorcycle Accessory Catalogue'', undated, p.4 Accessed 1 December 2017</ref></blockquote>\n\nWriting at his website in December 2010, American motorcycle design innovator [[Craig Vetter]] claimed to have \"created and developed\" from 1971 what he called ''Hippo Hands'', later sold to the public from 1973 by the Vetter organisation.<ref>[https://web.archive.org/web/20170501140352/http://www.craigvetter.com/pages/motorcycle_designs/Hippo-Hands-pages/Hippo-Hands-Main-page.html Hippo Hands (Archived from the original at craigvetter.com)], Archived 1 May 2017, Retrieved 1 December 2017</ref> These were very similar to a product that was easily available to UK motorcyclists from retail shops/mail order outlets from 1957,<ref name=\"Motor Cycle 1957\">''[[The Motor Cycle]]'', 7 March 1957, p.35. ''Claude Rye'' part-page advert ''NEW HANDLEBAR MUFFS Superior black waterproof leathercloth Handlebar Muffs, lined fleece, keep hands warm and dry. Pair 10/6. Deluxe pair 11/9, Post & Pkg. 1/6 M.P.C. Plastic 29/11 pair. P & P. 2/-.'' Accessed 12 September 2019</ref> with the description ''handlebar muffs''.<ref name=\"Motor Cycle 1962\">''[[The Motor Cycle]]'', 4 October 1962, ''Pride and Clarke'' single-page advert ''Special Offer - Handlebar muffs 12/6, postage 2/6'', p.31 Accessed 1 December 2017</ref><ref>[[The Motor Cycle|''Motor Cycle'']], 21 February 1963, ''Pride and Clarke'' double-page advert ''Handlebar muffs 17/6, postage 2/6'', pp.23-24 Accessed 1 December 2017</ref><ref>[[The Motor Cycle|''Motor Cycle'']], 21 February 1963, ''You say this'' reader's letters \"''Heated Muffs Experiment''\", p.230 Accessed 1 December 2017</ref><ref>[[The Motor Cycle|''Motor Cycle'']], 4 November 1965, ''Pride and Clarke'' double-page advert, ''Handlebar muffs 17/6, postage 3/0'', p.18 Accessed 1 December 2017</ref><ref name=\"Oxford\">[http://www.oxfordproducts.com/motorcycle/product_type/accessories/handlebar_accessories/muffs/ ''Muffs''], Oxford Products, Retrieved 1 December 2017</ref>\n\n==Notes==\n{{reflist}}\n\n==References==\n*{{EB1911|wstitle=Muff|volume=18|page=955}}\n{{commons category|Muffs}}\n\n{{Historical clothing}}\n{{Clothing}}\n\n{{DEFAULTSORT:Muff (Handwarmer)}}\n\n[[Category:Fashion accessories]]\n[[Category:Fur]]\n[[Category:Armwear]]\n", "name_user": "Rocknrollmancer", "label": "safe", "comment": "add a 1981 citation, no change to prose", "url_page": "//en.wikipedia.org/wiki/Muff_(handwarmer)"}
